NCT07142226View on ClinicalTrials.gov

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2027

Conditions
Biliary Tract Cancer
Interventions
GENETIC

Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS))

Peripheral blood will be collected from patients with advanced biliary tract cancer for circulating tumor DNA (ctDNA) testing. Next-generation sequencing (NGS) will be performed to detect clinically relevant genomic alterations, including IDH1 mutations, FGFR2 fusions, ERBB2 amplifications, and MSI-H/dMMR. The ctDNA results will be compared with tissue-based genomic profiling to evaluate concordance and clinical utility.

Trial Locations (1)

13496

Bundang CHA Medical Center, Seongnam-si

All Listed Sponsors
lead

CHA University

OTHER